HIGHLIGHTS
- who: Manyu Zhao from the (UNIVERSITY) have published the Article: Targeting fibrosis: mechanisms and clinical trials, in the Journal: (JOURNAL) of 17/06/2022
- what: The high mortality and complex pathogenesis of fibrotic diseases pose great challenges in clinical therapy.
- how: The previous results showed that GFT505 could inhibit steatosis inflammation and fibrosis in a NASH mouse model and reduce the expression of lipid metabolism- inflammation- and fibrosis-related signaling molecules323. Showed that most biomarkers of lipid inflammation and fibrosis were improved in both dose groups of lanifibranor.
- future: Studies have . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.